# Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)

> **NCT00915954** · NA · COMPLETED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 28 (actual)

## Conditions studied

- Acromegaly
- Type 2 Diabetes Mellitus

## Interventions

- **DIAGNOSTIC_TEST:** Oral Glucose Tolerance Test
- **DIAGNOSTIC_TEST:** Subcutaneous administration of recombinant human IGF-1
- **DIAGNOSTIC_TEST:** Placebo

## Key facts

- **NCT ID:** NCT00915954
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2013-08
- **Final completion:** 2014-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00915954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00915954, "Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00915954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*